Recent developments include leadership changes, quarterly financial results, and strategic outlook updates.

• AngioDynamics appointed Eric Honroth as President and CEO, succeeding James Clemmer who is retiring [N1].
• The company reiterated its fiscal year 2027 outlook in early October 2026 [N1].
• For the quarter ended August 31, 2026, AngioDynamics reported a net loss of $7.1 million on net sales of $80.9 million, with revenue growth driven by the Med Tech segment [N2][N3].
• Med Tech revenue grew 13.2% driven by increased sales of Auryon, NanoKnife, and thrombus management products [N2].
• Med Device revenue grew 1.4%, supported by Core and Microwave product sales, partially offset by softness in other product lines [N2].
• Gross margin improved to 59.4%, with Med Tech and Med Device segments showing margin expansion [N2].
• The company had a backlog of $2.7 million as of August 31, 2026 [N2].

AngioDynamics benefits from growth in its Med Tech segment, driven by innovative products such as NanoKnife and Auryon, which are gaining market traction. The company’s improving gross margins and expanding product portfolio support revenue growth. Its solid liquidity position and backlog provide operational stability. Leadership changes with the appointment of a new CEO may bring fresh strategic focus. The company’s investments in R&D and clinical trials underpin potential for new product introductions and market expansion. Increasing adoption of minimally invasive procedures and an aging population support demand for its devices.

The company faces risks from macroeconomic factors including inflation, tariffs, labor shortages, and supply chain disruptions that may impact costs and operations. Competitive pressures in the medical device market could affect pricing and market share. Regulatory challenges and reimbursement changes pose ongoing uncertainties. The company reported a net loss and continues to invest heavily in R&D and restructuring, which may pressure profitability. Leadership transition introduces execution risk. Market dynamics such as healthcare provider consolidation and value-based purchasing may impact sales and margins.

AngioDynamics' moat is supported by its diversified portfolio of specialized medical devices used in minimally invasive procedures, which require regulatory approvals and clinical validation. Its direct sales force in the U.S. and established distributor relationships internationally provide market access. The company’s focus on innovation, including products like NanoKnife and Auryon, and ongoing investments in R&D contribute to product differentiation. Additionally, its presence in multiple medical specialties and the complexity of healthcare provider purchasing decisions create barriers to entry for competitors. However, the medical device industry is competitive and subject to regulatory and reimbursement risks.

• Macroeconomic and Supply Chain Risks: Inflation, tariffs, labor shortages, and supply chain challenges including raw material costs and availability may adversely affect manufacturing and costs [S2].
• Regulatory and Reimbursement Risks: Changes in FDA regulations, healthcare reforms, and reimbursement policies could impact product approvals, market access, and pricing [S2].
• Competitive Risks: The medical device industry is highly competitive with companies having greater resources, which may affect AngioDynamics' market share and pricing power [S2].
• Execution Risks from Leadership Transition: The recent CEO change introduces risks related to strategic continuity and execution of growth initiatives [N1].
• Profitability and Financial Risks: The company reported net losses and continues to invest in R&D and restructuring, which may pressure margins and cash flow [S2].

• AngioDynamics, Inc. is a diversified medical technology company focused on cardiovascular disease and cancer treatment devices used in minimally invasive, image-guided procedures [S2].
• The company designs, manufactures, and sells medical, surgical, and diagnostic devices primarily used by healthcare professionals such as interventional radiologists, cardiologists, vascular surgeons, urologists, oncologists, and critical care nurses [S2].
• Products include vascular access devices, peripheral vascular disease treatment devices, oncology and surgical devices, many of which are disposable or temporarily implanted [S2].
• Sales are primarily direct in the U.S. and through distributors internationally [S2].
• The company’s business is influenced by healthcare market dynamics including value-based purchasing, provider consolidation, consumer healthcare decision-making, and an aging population [S2].
• AngioDynamics invests in research and development and selective business development to expand product offerings and growth opportunities [S2].
• For the three months ended August 31, 2026, net sales were $80.9 million, a 6.9% increase from the prior year period, driven by 13.2% growth in Med Tech and 1.4% growth in Med Device segments [S2].
• Med Tech segment includes Auryon, NanoKnife, and thrombus management platforms; growth driven by increased sales in these products [S2].
• Med Device segment growth driven by Core and Microwave product lines, partially offset by softness in Venous, Ports, and other Oncology product lines [S2].
• Gross margin for the quarter increased to 59.4% from 55.3% the prior year, with Med Tech gross margin at 66.2% and Med Device at 52.7% [S2].
• Net loss for the quarter was $7.1 million, an improvement from a $10.9 million loss in the prior year quarter; diluted loss per share was $0.17 [S2].
• Liquidity as of August 31, 2026 included $33.97 million in cash and equivalents, $143.0 million in current assets, and $59.7 million in current liabilities, yielding a current ratio of 2.4 and a cash ratio of 0.8 [S2].
• The company had a backlog of $2.7 million as of August 31, 2026 [S2].
• Recent leadership change: Eric Honroth appointed President and CEO, succeeding James Clemmer who announced retirement [N1].
• The company reiterated its fiscal year 2027 outlook in October 2026 [N1].
• The company’s Med Tech segment is anticipated to become the majority of revenue in fiscal 2027 [N6].
• The company faces macroeconomic challenges including inflation, tariffs, labor shortages, supply chain issues, and regulatory risks [S2].